Denali Q1 net loss widens to $109.8M; Biogen licenses ATV:Abeta, DNL310 positive data

Denali Therapeutics Inc.

2023-Q1 EPS reported -$0.80 revenue$35,141,000

Net loss $109.8M vs $65.2M YoY; collaboration revenue $35.1M vs $42.1M.
R&D expenses rose to $128.8M from $86.1M; cash & securities $1.29B at March 31.
Biogen exercised option to license ATV:Abeta; Denali receives option payment and milestones.
DNL310 Phase 1/2 interim data showed improved behavior/cognition; COMPASS study enrolling.
Triggered $30M contingent consideration for F-star Gamma; $10M milestone from Takeda for DNL593.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-23-000074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.